Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
NCT07571161Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Primary completion
- Apr 2030
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score. Started Apr 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07571161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571161.